Results 171 to 180 of about 10,634,853 (332)

In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock   +8 more
wiley   +1 more source

Association of the ICH Score With Withdrawal of Life‐Sustaining Treatment Over a 10‐Year Period

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The intracerebral hemorrhage (ICH) score was developed to enhance provider communication and facilitate early severity assessment. We examined the association of the ICH score with mortality and withdrawal of life‐sustaining treatment (WLST) in a large, multicenter stroke registry, and evaluated temporal trends in these associations.
Nina Massad   +15 more
wiley   +1 more source

Tick-Borne Infectious Diseases in China, 2003-2023. [PDF]

open access: yesChina CDC Wkly
Zhu Y   +6 more
europepmc   +1 more source

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis. Methods Clinical information was collected prospectively on Research Electronic Data Capture.
Nabil K. El Ayoubi   +6 more
wiley   +1 more source

Nanomedicine for Infectious Diseases [PDF]

open access: yesNanomedicine, 2020
Harald Unterweger   +6 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy